IRIS
DE GIORGI, UGO FEDERICO FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 4.851
NA - Nord America 3.753
EU - Europa 1.316
SA - Sud America 495
Continente sconosciuto - Info sul continente non disponibili 449
AF - Africa 59
OC - Oceania 1
Totale 10.924
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.488
HK - Hong Kong 2.195
SG - Singapore 1.757
IT - Italia 1.115
BR - Brasile 422
CN - Cina 359
VN - Vietnam 189
BD - Bangladesh 146
CA - Canada 113
IN - India 87
GB - Regno Unito 72
MX - Messico 46
JM - Giamaica 26
AR - Argentina 25
IQ - Iraq 20
CR - Costa Rica 18
ZA - Sudafrica 18
EC - Ecuador 14
NL - Olanda 14
TR - Turchia 14
DE - Germania 13
HN - Honduras 13
SA - Arabia Saudita 13
RO - Romania 11
UZ - Uzbekistan 11
CO - Colombia 10
PL - Polonia 10
UA - Ucraina 10
FR - Francia 9
PK - Pakistan 9
RU - Federazione Russa 9
ES - Italia 8
ID - Indonesia 8
JP - Giappone 8
MA - Marocco 8
PR - Porto Rico 8
TN - Tunisia 8
BB - Barbados 7
EE - Estonia 7
GT - Guatemala 7
CL - Cile 6
LT - Lituania 6
SV - El Salvador 6
UY - Uruguay 6
AT - Austria 5
DZ - Algeria 5
ET - Etiopia 5
IE - Irlanda 5
KE - Kenya 5
VE - Venezuela 5
CW - ???statistics.table.value.countryCode.CW??? 4
EG - Egitto 4
NI - Nicaragua 4
NP - Nepal 4
PY - Paraguay 4
TT - Trinidad e Tobago 4
AZ - Azerbaigian 3
JO - Giordania 3
MD - Moldavia 3
OM - Oman 3
PH - Filippine 3
PS - Palestinian Territory 3
SE - Svezia 3
AE - Emirati Arabi Uniti 2
BM - Bermuda 2
BS - Bahamas 2
CZ - Repubblica Ceca 2
DO - Repubblica Dominicana 2
FI - Finlandia 2
GH - Ghana 2
GP - Guadalupe 2
KG - Kirghizistan 2
KR - Corea 2
KZ - Kazakistan 2
LV - Lettonia 2
MY - Malesia 2
PT - Portogallo 2
AL - Albania 1
AU - Australia 1
BE - Belgio 1
BG - Bulgaria 1
CG - Congo 1
CU - Cuba 1
CY - Cipro 1
GE - Georgia 1
GF - Guiana Francese 1
GR - Grecia 1
GY - Guiana 1
HT - Haiti 1
HU - Ungheria 1
IL - Israele 1
IR - Iran 1
LC - Santa Lucia 1
LY - Libia 1
MK - Macedonia 1
NO - Norvegia 1
PA - Panama 1
PE - Perù 1
QA - Qatar 1
RS - Serbia 1
Totale 10.475
Salva come PNG Salva come JPEG
Città #
Hong Kong 2.193
Council Bluffs 889
Ashburn 602
Milan 376
San Jose 298
Singapore 276
Santa Clara 129
Rome 88
Beijing 75
Miano 69
New York 64
Los Angeles 58
Ho Chi Minh City 54
Hanoi 52
Naples 51
Mumbai 40
Dallas 33
São Paulo 31
Mexico City 24
Montreal 23
Chicago 20
Figino 20
Atlanta 18
North Bergen 18
Philadelphia 17
Orem 16
Tampa 16
Toronto 16
Bologna 15
Dhaka 14
Florence 14
Kingston 14
San Francisco 14
Turin 14
Buffalo 13
Da Nang 13
Houston 13
London 12
San José 12
Bar Harbor 11
Palermo 11
Las Vegas 10
Rio de Janeiro 10
Warsaw 10
Bari 9
San Pietro Vernotico 9
Tashkent 9
Baghdad 8
Brasília 8
Brooklyn 8
Memphis 8
Miami 8
Biên Hòa 7
Boardman 7
Brescia 7
Cagliari 7
Charlotte 7
Denver 7
Guatemala City 7
New Delhi 7
Porto Alegre 7
San Pedro Sula 7
Thái Nguyên 7
Tokyo 7
Venice 7
Bridgetown 6
Catania 6
Fort Lauderdale 6
Goiânia 6
Johannesburg 6
Orlando 6
Phoenix 6
Salvador 6
San Salvador 6
Seattle 6
The Bronx 6
Verona 6
Washington 6
Addis Ababa 5
Chennai 5
Columbus 5
Genoa 5
Guayaquil 5
Haiphong 5
Indianapolis 5
Manchester 5
Milwaukee 5
Nairobi 5
Newark 5
Queens 5
Reggio Emilia 5
Riyadh 5
San Diego 5
Santiago 5
The Dalles 5
Winnipeg 5
Cape Town 4
Caxias do Sul 4
Chiarano 4
Cotia 4
Totale 6.108
Salva come PNG Salva come JPEG
Nome #
68Ga-PSMA-PET: added value and future applications in comparison to the current use of choline-PET and mpMRI in the workup of prostate cancer 127
18F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide 127
A comparison of methods of loco-regional chemotherapy combined with systemic chemotherapy as neo-adjuvant treatment of osteosarcoma of the extremity 124
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. 113
Characterization of metastatic breast cancer patients with nondetectable circulating tumor cells. 97
Prevention and therapy of neutropenia in elderly patients 94
Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer 94
Adjuvant Carboplatin Treatment in 115 Patients With Stage I Seminoma: Retrospective Multicenter Survey 93
Addition of androgen receptor targeted agents to androgen deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis 91
68 Ga-PSMA PET/CT in patients with recurrent prostate cancer after radical treatment: prospective results in 314 patients 90
A comprehensive review of the role of immune checkpoint inhibitors in elderly patients affected by renal cell carcinoma 86
A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients 85
Circulating androgen receptor gene amplification and resistance to 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: results of a Phase 2 trial 84
First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial 83
Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial 82
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial 77
PSMA expression: A potential ally for the pathologist in prostate cancer diagnosis 76
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial 75
Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: an up-to-date review and meta-analysis of clinical trials 73
Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer 73
Adjuvant high-dose chemotherapy with autologous hematopoietic stem cell transplantation for high-risk breast cancer: results from the italian National Registry 71
Plasma androgen receptor and response to adapted and standard docetaxel regimen in castration-resistant prostate cancer: A multicenter biomarker study 71
[177 Lu]-PSMA-617 for targeted prostate cancer treatment: a magic bullet? 71
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial 70
Anticancer drug delivery with nanoparticles 70
Adjuvant high-dose chemotherapy with autologous hematopoietic stem cell transplantation for high-risk breast cancer: results from the italian National Registry 70
Conditional survival of patients treated with first-line chemotherapy for metastatic urothelial cancer 69
Adjuvant concomitant chemotherapy in pancreatic cancer. 69
PSMA expression: a potential ally for the pathologist in prostate cancer diagnosis 68
18F-FDG PET/CT findings and circulating tumor cell counts in the monitoring of systemic therapies for bone metastases 67
A sequential chemo-radiotherapeutic treatment for patients with malignant gliomas: a phase II pilot study 66
A fully virtual and nationwide molecular tumor board for gynecologic cancer patients: the virtual experience of the MITO cooperative group 66
Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma 66
A randomized study comparing filgrastim versus lenograstim versus molgramostim plus chemotherapy for peripheral blood progenitor cell mobilization 65
International evaluation of the psychometrics of health-related quality of life questionnaires for use among long-term survivors of testicular and prostate cancer 64
A Phase II study of everolimus plus oral prednisone in patients with metastatic renal cell cancer 64
Long-term clinical impact of PSA surge in castration-resistant prostate cancer patients treated with abiraterone 63
A phase II study of a dose-density regimen with fluorouracil, epirubicin, and cyclophosphamide on days 1 and 4 every 14 days with filgrastim support followed by weekly paclitaxel in women with primary breast cancer 62
18F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide 61
Combining liquid biopsy and functional imaging analysis in metastatic castration-resistant prostate cancer helps predict treatment outcome 60
Multiple cycles of PBPC-supported high-dose carboplatin and paclitaxel following mobilization with epirubicin and cisplatin are feasible but ineffective in treating patients with advanced non-small cell lung cancer 59
[18F]fluorodeoxyglucose positron emission tomography for outcome prediction of mammalian target of rapamycin inhibitor therapy. 59
Immunotherapy and its development for gynecological (Ovarian, endometrial and cervical) tumors: From immune checkpoint inhibitors to chimeric antigen receptor (car)-T cell therapy 59
Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination 58
Salvage high-dose chemotherapy in female patients with relapsed/refractory germ cell tumors: a retrospective analysis of the European Group for Blood and Marrow Transplantation (EBMT) 58
Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. 58
Clinical pharmacology of intraperitoneal cisplatin-based chemotherapy. 57
Long-term outcome of salvage high-dose chemotherapy in patients with germ cell tumor with poor prognostic features 57
Germ cell tumours of the testis 57
Prognostic Role of Systemic Inflammatory Indexes in Germ Cell Tumors Treated With High-Dose Chemotherapy 57
Neoadjuvant endocrine therapy for luminal breast tumors: State of the art, challenges and future perspectives 56
Inflammatory indexes as predictive factors for platinum sensitivity and as prognostic factors in recurrent epithelial ovarian cancer patients: a MITO24 retrospective study 55
Long-term follow-up of patients with poor prognosis germ cell tumor treated with early high-dose chemotherapy with hematopoietic progenitor cell support: a single-center experience 54
Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial 54
Adjuvant high-dose chemotherapy with autologous hematopoietic stem cell support for high-risk primary breast cancer: Results from the Italian national registry 54
Hydroxychloroquine as Prophylaxis for COVID-19: A Review 53
Clinical outcomes in a contemporary series of "young" patients with castration-resistant prostate cancer who were 60 years and younger 53
Ovarian Sertoli-Leydig cell tumor, endometrioid-like yolk sac tumor, and Y-chromosomal material 52
Real-world experience and clinical impact of drug-drug interactions in HR+/HER2- advanced breast cancer patients treated with abemaciclib plus endocrine therapy: the AB-ITALY study 52
Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer 52
Plasma androgen receptor and serum chromogranin A in advanced prostate cancer 52
Radical cystectomy or bladder preservation with radiochemotherapy in elderly patients with muscle-invasive bladder cancer: Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators 51
Inherited Mutations in DNA Damage Repair Genes in Italian Men with Metastatic Prostate Cancer: Results from the Meet-URO 10 Study 51
Circulating tumor cells (CTCs) are associated with abnormalities in peripheral blood dendritic cells in patients with inflammatory breast cancer 51
Ki67 and PR in patients treated with CDK4/6 Inhibitors: A real-world experience 50
Global approach to hepatic metastases from colorectal cancer: indication and outcome of intra-arterial chemotherapy and other hepatic-directed treatments 50
Potential Impact of Preoperative Circulating Biomarkers on Individual Escalating/de-Escalating Strategies in Early Breast Cancer 49
Neuroendocrine differentiation in prostate cancer: Current and emerging therapy strategies 49
Relationship between lymphocytopenia and circulating tumor cells as prognostic factors for overall survival in metastatic breast cancer 49
Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy 49
High-dose chemotherapy for adult-type ovarian granulosa cell tumors: a retrospective study of the European Society for Blood and Marrow Transplantation 48
Circulating androgen receptor combined with 18F-fluorocholine PET/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prostate cancer 48
CDK4/6-Inhibitors Versus Chemotherapy in Advanced HR+/ HER2-Negative Breast Cancer: Results and Correlative Biomarker Analyses of the KENDO Randomized Phase II Trial 48
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial 47
Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone 47
Cell-free DNA as a diagnostic marker for cancer: current insights 47
Autologous hematopoietic stem cell transplantation for breast cancer in Europe: critical evaluation of data from the European Group for Blood and Marrow Transplantation (EBMT) Registry 1990-1999 47
Systemic immune-inflammation index predicts the clinical outcome in patients with mCRPC treated with abiraterone 46
Lymphopenia and clinical outcome of elderly patients treated with sunitinib for metastatic renal cell cancer 46
Clinical outcomes of castration-resistant prostate cancer treatments administered as third or fourth line following failure of docetaxel and other second-line treatment: Results of an Italian multicentre study 46
Dose intensification in hormone receptor–negative and/or human epidermal growth factor receptor 2–negative high-risk primary breast cancer. 46
Tyrosine kinase inhibitor imatinib mesylate as anticancer agent for advanced ocular melanoma expressing immunoistochemical C-KIT (CD 117): preliminary results of a compassionate use clinical trial 46
High neutrophil-to-lymphocyte ratio persistent during first-line chemotherapy predicts poor clinical outcome in patients with advanced urothelial cancer 45
The prognostic value of pain in castration-sensitive prostate cancer 44
Role of DNA repair machinery and p53 in the testicular germ cell cancer: A review 44
Is high-dose chemotherapy after primary chemotherapy a therapeutic option for patients with primary mediastinal nonseminomatous germ cell tumor? 43
Immunotherapy for prostate cancer: Where we are headed 42
Real-life clinical practice results with vinflunine in patients with relapsed platinum-treated metastatic urothelial carcinoma: an Italian multicenter study 42
Weekly gemcitabine, paclitaxel, oxaliplatin combination chemotherapy in patients with Cisplatin-refractory germ cell tumor: preliminary experience 42
GSTP1 Methylation and Protein Expression in Prostate Cancer: Diagnostic Implications 42
First-Line PAzopanib in NOn–clear-cell Renal cArcinoMA: The Italian Retrospective Multicenter PANORAMA Study 42
Consider quality of life to improve quality of cancer guidelines 41
Circulating androgen receptor combined with 18F-fluorocholine PET/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prostate cancer 41
Pharmacokinetics, pharmacodynamics and clinical efficacy of nivolumab in the treatment of metastatic renal cell carcinoma 41
Lenvatinib in the management of metastatic renal cell carcinoma: a promising combination therapy? 41
Locoregional treatment of de novo stage IV breast cancer in the era of modern oncology 41
Value of pharmacokinetic studies for patients with gastrointestinal stromal tumors 40
Re: Pasquale Rescigno, David Lorente, Diletta Bianchini, et al. Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. 40
First-line high-dose chemotherapy for patients with poor prognosis extragonadal germ cell tumors: the experience of the European Bone Marrow Transplantation (EBMT) Solid Tumors Working Party 40
Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib 40
Totale 6.105
Salva come PNG Salva come JPEG
Categoria #
all - tutte 45.461
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 45.461
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2024/20252.898 0 0 0 0 0 0 315 6 1.345 704 213 315
2025/20263.510 635 795 274 197 129 126 353 188 251 328 103 131
2026/20274.516 444 877 971 2.224 0 0 0 0 0 0 0 0
Totale 10.924